Cardio Diagnostics Holdings, Inc. (CDIO) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$1.50M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$1.78M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$1.71M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$1.68M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$1.50M | (m) | (m) | (m) | $0.00* | -$1.34M* | (m) | $162.93K | (m) | (m) |
| 2026-03-31 | Reported | (m) | -$1.78M | (m) | (m) | (m) | $1.76K | -$1.56M | (m) | $129.78K | (m) | (m) |
| 2025-09-30 | Reported | (m) | -$1.71M | (m) | (m) | (m) | $162.83K* | -$1.39M* | (m) | $189.05K | $1.71M | (m) |
| 2025-06-30 | Reported | (m) | -$1.68M | (m) | (m) | (m) | $18.70K* | -$1.57M* | (m) | $178.54K | $1.69M | (m) |
| 2025-03-31 | Reported | (m) | -$1.63M | (m) | (m) | (m) | $5.79K | -$1.40M | (m) | $118.78K | (m) | (m) |
| 2024-09-30 | Reported | (m) | -$1.41M | (m) | (m) | (m) | $23.25K* | -$1.16M* | (m) | $5.25K | $1.42M | (m) |
| 2024-06-30 | Reported | (m) | -$1.28M | (m) | (m) | (m) | $167.90K* | -$1.21M* | (m) | $7.28K | $1.29M | (m) |
| 2024-03-31 | Reported | (m) | -$4.16M | (m) | (m) | (m) | $19.98K | -$1.23M | (m) | $10.84K | (m) | (m) |
| 2023-09-30 | Reported | (m) | -$1.44M | (m) | (m) | (m) | $12.59K* | -$1.04M* | (m) | $38.71K | (m) | $0.00 |
| 2023-06-30 | Reported | (m) | -$2.55M | (m) | (m) | (m) | (m) | -$1.29M* | (m) | $12.32K | (m) | $0.00 |
| 2023-03-31 | Reported | (m) | -$1.70M | (m) | (m) | (m) | (m) | -$1.65M | (m) | $86.67K | (m) | $0.00 |
| 2022-09-30 | Reported | (m) | -$1.15M | (m) | (m) | (m) | $0.00* | -$1.39M* | (m) | $3.19K | (m) | $0.00 |
| 2022-06-30 | Reported | (m) | -$786.96K | (m) | (m) | (m) | (m) | -$394.77K* | (m) | $5.04K | (m) | $0.00 |
| 2022-03-31 | Reported | (m) | -$227.09K | (m) | (m) | (m) | (m) | -$186.09K | (m) | $1.13K | (m) | $0.00 |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$6.48M | (m) | (m) | (m) | $187.32K | -$5.73M | (m) | $641.21K | (m) | (m) |
| 2024-12-31 | Reported | (m) | -$8.37M | (m) | (m) | (m) | $214.76K | -$4.99M | (m) | $227.97K | (m) | (m) |
| 2023-12-31 | Reported | (m) | -$7.24M | (m) | (m) | (m) | $575.66K | -$5.67M | (m) | $145.18K | (m) | (m) |
| 2022-12-31 | Reported | (m) | -$4.55M | (m) | (m) | (m) | (m) | -$5.09M | (m) | $40.45K | (m) | $0.00 |
| 2021-12-31 | Reported | (m) | -$620.45K | (m) | (m) | (m) | (m) | -$585.29K | (m) | $31.47K | (m) | $0.00 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |